Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Systematic Review
Authors: Sagües-Sesé, Elenaa | Rioja, Joséa; b; c | Garzón-Maldonado, Francisco J.c; d | Narváez, Manuela; c | García-Arnés, Juan A.a | García-Casares, Nataliaa; b; c; *
Affiliations: [a] Facultad de Medicina, Universidad de Málaga, Málaga, Spain | [b] Centro de Investigaciones Médico-Sanitarias (CIMES), Málaga, Spain | [c] Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain | [d] Departamento de Neurología, Hospital Universitario Virgen de la Victoria de Málaga, Málaga, Spain
Correspondence: [*] Correspondence to: Natalia García-Casares, MD, PhD, Departamento de Medicina, Facultad de Medicina, Universidad de Málaga, Boulevard Louis Pasteur 32, C.P 29071 Málaga, Spain. E-mails: nagcasares@uma.es and nagcasares@gmail.com.
Note: [1] This article received a correction notice (Erratum) with the reference: 10.3233/JAD-JAD249011, available at http://doi.org/10.3233/JAD-249011.
Abstract: Background:Glucose metabolism and insulin signaling alterations play an important role in Alzheimer’s disease (AD) pathogenesis. Researchers have extensively attempted to characterize the exact pathophysiological mechanisms in the cerebrospinal fluid (CSF), as evidence concerning this fluid biomarkers is expected to enhance AD diagnosis’ specificity and accuracy and serve as an early disease detection tool. There is controversy about insulin levels in the CSF relationship with mild cognitive impairment (MCI) and AD. Objective:This systematic review provides an overview of the state-of-the-art knowledge about insulin-related CSF biomarkers in AD and MCI. Methods:We performed a qualitative systematic literature review of reported data of CSF glucose, insulin, or insulin-related molecules in humans with AD or MCI, consulting the electronic databases Medline, Scopus, Web of Science, Cochrane, and BASE until May 2022. Results:We selected 19 studies, 10 of them reporting data on CSF insulin and 8 on insulin-related molecules like growth factors or their binding proteins. They predominantly found decreased levels of CSF insulin and increased levels of CSF insulin-related growth factors and their binding proteins. Conclusion:Due to the studies’ protocols and results heterogeneity, we recommend a larger database of clinical trials with similar characteristics for a better understanding of this relationship.
Keywords: Alzheimer’s disease, biomarkers, cerebrospinal fluid, glucose, insulin, insulin-growth factor, mild cognitive impairment
DOI: 10.3233/JAD-220688
Journal: Journal of Alzheimer's Disease, vol. 90, no. 1, pp. 1-13, 2022
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
sales@iospress.com
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
info@iospress.nl
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office info@iospress.nl
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
china@iospress.cn
For editorial issues, like the status of your submitted paper or proposals, write to editorial@iospress.nl
如果您在出版方面需要帮助或有任何建, 件至: editorial@iospress.nl